Sun Pharma Adv. Res Stock Price Analysis and Quick Research Report. Is Sun Pharma Adv. Res an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sun Pharma Adv. Res. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sun Pharma Adv. Res has a PE ratio of -15.6141298476828 which is low and comparatively undervalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sun Pharma Adv. Res has ROA of -84.6538% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sun Pharma Adv. Res has a Current ratio of 0.0676.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sun Pharma Adv. Res has a ROE of 0%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sun Pharma Adv. Res has a Debt to Equity ratio of -1.1703 which means that the company has low proportion of debt in its capital.

• Sales growth: Sun Pharma Adv. Res has reported revenue growth of -5.0027% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sun Pharma Adv. Res for the current financial year is -456.033637098347%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sun Pharma Adv. Res is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sun Pharma Adv. Res is Rs -9.257. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sun Pharma Adv. Res in Ticker for free. Also, one can get the intrinsic value of Sun Pharma Adv. Res by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sun Pharma Adv. Res FAQs

Q1. What is Sun Pharma Adv. Res share price today?
Ans: The current share price of Sun Pharma Adv. Res is Rs 144.54.

Q2. What is the market capitalisation of Sun Pharma Adv. Res?
Ans: Sun Pharma Adv. Res has a market capitalisation of Rs 4690.635032952 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sun Pharma Adv. Res?
Ans: The PE ratio of Sun Pharma Adv. Res is -15.6141298476828 and the P/B ratio of Sun Pharma Adv. Res is -17.203865930299, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sun Pharma Adv. Res share?
Ans: The 52-week high share price of Sun Pharma Adv. Res is Rs 241, and the 52-week low share price of Sun Pharma Adv. Res is Rs 109.3.

Q5. Does Sun Pharma Adv. Res pay dividends?
Ans: Currently, Sun Pharma Adv. Res does not pay dividends. Dividend yield of Sun Pharma Adv. Res is around 0%.

Q6. What are the face value and book value of Sun Pharma Adv. Res shares?
Ans: The face value of Sun Pharma Adv. Res shares is Rs 1, while the book value per share of Sun Pharma Adv. Res is around Rs -8.4016. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sun Pharma Adv. Res?
Ans: Sun Pharma Adv. Res has a total debt of Rs 258.1853 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sun Pharma Adv. Res?
Ans: The ROE of Sun Pharma Adv. Res is 0% and ROCE of Sun Pharma Adv. Res is -321.1849%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sun Pharma Adv. Res a good buy for the long term?
Ans: The Sun Pharma Adv. Res long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sun Pharma Adv. Res undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sun Pharma Adv. Res appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sun Pharma Adv. Res’s financials?
Ans: You can review Sun Pharma Adv. Res’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.